Evidence Hub

Secondary Hyperparathyroidism in CKD: Comparative Case Series of Medical Management and Parathyroidectomy

B. H, Aleesha Prakash, Khadheeja M, L. R., Binu Upendran

International Journal of Medical and Pharmaceutical Case Reports, 2025

Abstract

In chronic kidney disease (CKD), disturbances in phosphate, calcium, and vitamin D balance often lead to secondary hyperparathyroidism (SHPT), which can progress to tertiary hyperparathyroidism if left untreated.

We present three cases illustrating different management approaches: a 36-year-old male with refractory SHPT successfully treated with total parathyroidectomy, thymectomy, and forearm auto transplantation; a 63-year-old female on long-term dialysis who developed a spinal brown tumor from tertiary hyperparathyroidism, managed with parathyroidectomy and spinal decompression; and a 43-year-old male with stage V CKD whose SHPT was effectively controlled medically with Sevelamer, Alfacalcidol, and Cinacalcet.

These cases emphasize that while medical therapy is effective in early, responsive SHPT, advanced or refractory disease often requires surgical intervention, highlighting the importance of timely diagnosis, individualized treatment, and multidisciplinary follow-up for optimal outcomes.

How strong is the evidence?

Evidence Hub reads this as a case series, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free